Generation Bio CO Form 4 insider transactions
Generation Bio Co. Director Jason P. Rhodes was granted 30,000 stock options with an exercise price of $0.3874, vesting by June 2026.
Generation Bio Co. Director Charles A. Rowland Jr. was granted 30,000 stock options with an exercise price of $0.3874, aligning his interests with shareholder value.
Dannielle Appelhans, a Director at Generation Bio Co., was granted 30,000 stock options with an exercise price of $0.3874, aligning her interests with shareholders.
Generation Bio Co. Director Ronald Harold Wilfred Cooper was granted 30,000 stock options with an exercise price of $0.3874, set to vest by June 2026.
Anthony G. Quinn, a Director at Generation Bio Co. (GBIO), was granted 30,000 stock options with an exercise price of $0.3874, aligning his interests with long-term shareholder value.
Jeffrey M. Jonas, a Director at Generation Bio Co. (GBIO), was granted 30,000 stock options with an exercise price of $0.3874, aligning his interests with shareholder value.
Generation Bio Co. Director Donald William Nicholson was granted 30,000 stock options with an exercise price of $0.3874, vesting by June 2026.
Catherine Stehman-Breen, a Director at Generation Bio Co., was granted 30,000 stock options with an exercise price of $0.3874, vesting by June 2026.
Chief Financial Officer Kevin John Conway of Generation Bio Co. reports the vesting and subsequent disposal of common stock to cover tax obligations.
Phillip Samayoa, Chief Scientific Officer of Generation Bio Co., reports the acquisition and disposal of common stock and restricted stock units.
CEO Geoff McDonough reports the vesting and subsequent disposal of shares related to restricted stock units, along with adjustments to holdings in family trusts.
Antoinette Paone, Chief Operating Officer of Generation Bio Co., reports the disposition of common stock and restricted stock units to cover tax obligations.
Yalonda Howze, Chief Legal Officer of Generation Bio Co., reports the vesting and subsequent disposal of shares related to restricted stock units.
Kevin John Conway, Chief Financial Officer of Generation Bio Co., reports the vesting and disposal of restricted stock units.
Yalonda Howze, Chief Legal Officer of Generation Bio Co., reports the vesting and subsequent disposal of shares to cover tax obligations.
Phillip Samayoa, Chief Scientific Officer of Generation Bio Co., reports the vesting and subsequent sale of restricted stock units.
Antoinette Paone, Chief Operating Officer of Generation Bio Co., reports the vesting and subsequent disposal of shares to cover tax obligations.
CEO Geoff McDonough reports the vesting and disposal of restricted stock units, along with adjustments to his direct and indirect holdings of Generation Bio Co. common stock.
Generation Bio Co.'s Chief Financial Officer, Kevin John Conway, was granted stock options for 355,260 shares on January 10, 2025.
Director Anthony G. Quinn increased his holdings in Generation Bio Co. (GBIO) through open market purchases.
Phillip Samayoa, Chief Scientific Officer of Generation Bio Co., reports acquisition of shares through employee stock purchase plan and grant of stock options.
Antoinette Paone, Chief Operating Officer of Generation Bio Co., reports acquisition of shares through employee stock purchase plan and grant of stock options.
Geoff McDonough, CEO of Generation Bio Co., reports acquisition of shares and options, including those held directly and indirectly through family trusts.
Yalonda Howze, Chief Legal Officer of Generation Bio Co., was granted stock options to purchase 251,030 shares of common stock on January 10, 2025.
Matthew Norkunas, CFO of Generation Bio Co., will no longer serve in his role effective January 10, 2025, and will cease filing Section 16 reports.
Matthew Stanton, Chief Scientific Officer of Generation Bio Co., will no longer be subject to Section 16 reporting requirements due to his departure from the company effective January 10, 2025.
Matthew Stanton, Chief Scientific Officer of Generation Bio Co., reports the vesting and subsequent disposal of restricted stock units.
Phillip Samayoa, Chief Strategy Officer at Generation Bio Co., reports the vesting and subsequent disposal of shares related to restricted stock units.
Matthew Norkunas, CFO of Generation Bio Co., reports the acquisition and disposal of common stock and restricted stock units.
CEO Geoff McDonough reports the vesting and sale of restricted stock units, along with adjustments to his direct and indirect holdings of Generation Bio Co. stock.